Hereditary thrombocytopenia and hematological cancer predisposition syndrome associated with RUNX1
MONDO:0100083This is an autosomal dominant disorder caused by mutations in the RUNX1 gene and is characterized by mild to moderate thrombocytopenia, platelet functional and/or ultrastructural defects and a predisposition to hematologic malignancies, most often AML and MDS, and less frequently T-ALL.
Also known as: FPD/AML syndrome, FPS/AML syndrome, Familial Platelet Disorder with Associated Myeloid Malignancy, familial platelet disorder with associated myeloid malignancy, familial platelet syndrome with predisposition to acute myelogenous leukaemia, familial platelet syndrome with predisposition to acute myelogenous leukemia, hereditary thrombocytopenia and hematological cancer predisposition syndrome associated with RUNX1, FPDMM
79 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
New CAR-T therapy targets antibodies blocking Life-Saving transplants
Disease control Not yet recruitingThis early-stage study tests a new treatment using special immune cells (CAR-T cells) designed to reduce harmful antibodies that can prevent or damage bone marrow transplants. About 18 people with blood diseases who have these antibodies will receive the cells in increasing doses…
Phase: PHASE1, PHASE2 • Sponsor: Chang Yingjun • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Could a feeding tube after transplant save the gut?
Disease control Not yet recruitingThis study tests whether starting tube feeding right after a stem cell transplant can reduce severe gut graft-versus-host disease (GVHD) in people with blood cancers or disorders. About 112 participants will be randomly assigned to either standard care or early tube feeding. The …
Phase: PHASE2 • Sponsor: University of Nebraska • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Ginger vs. heavy periods: a natural approach for women with bleeding disorders
Symptom relief Not yet recruitingThis study tests whether taking ginger powder for the first three days of each period can reduce heavy menstrual bleeding in women with coagulation disorders (bleeding problems). 74 women will be randomly assigned to receive either ginger or a placebo for six cycles. The goal is …
Phase: EARLY_PHASE1 • Sponsor: University of Valladolid • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
New online tool aims to help families uncover hidden cancer risks
Knowledge-focused Not yet recruitingThis study tests whether a new online program can help families understand their inherited cancer risk and encourage relatives to get low-cost genetic testing. Researchers will enroll 400 adults who carry a cancer-related gene change and their family members. The goal is to see i…
Phase: NA • Sponsor: Stanford University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
50,000 samples to unlock secrets of hereditary tumors
Knowledge-focused Not yet recruitingThis study will collect blood and tumor tissue from up to 50,000 adults with hereditary or genetic-linked cancers. Researchers will use these samples to create lab-grown tumor models, like mini-tumors, to study how these cancers work and test new treatments. The goal is to better…
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC